These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 33300950)

  • 41. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.
    Zielinski C; Láng I; Inbar M; Kahán Z; Greil R; Beslija S; Stemmer SM; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Petruzelka L; Eniu A; Nisenbaum B; Dank M; Anghel R; Messinger D; Brodowicz T;
    Lancet Oncol; 2016 Sep; 17(9):1230-9. PubMed ID: 27501767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.
    Steenbruggen TG; Steggink LC; Seynaeve CM; van der Hoeven JJM; Hooning MJ; Jager A; Konings IR; Kroep JR; Smit WM; Tjan-Heijnen VCG; van der Wall E; Bins AD; Linn SC; Schaapveld M; Jacobse JN; van Leeuwen FE; Schröder CP; van Tinteren H; de Vries EGE; Sonke GS; Gietema JA
    JAMA Oncol; 2020 Apr; 6(4):528-534. PubMed ID: 31999296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial.
    Hui Z; Men Y; Hu C; Kang J; Sun X; Bi N; Zhou Z; Liang J; Lv J; Feng Q; Xiao Z; Chen D; Wang Y; Li J; Wang J; Gao S; Wang L; He J
    JAMA Oncol; 2021 Aug; 7(8):1178-1185. PubMed ID: 34165501
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.
    Colleoni M; Gray KP; Gelber S; Láng I; Thürlimann B; Gianni L; Abdi EA; Gomez HL; Linderholm BK; Puglisi F; Tondini C; Kralidis E; Eniu A; Cagossi K; Rauch D; Chirgwin J; Gelber RD; Regan MM; Coates AS; Price KN; Viale G; Goldhirsch A
    J Clin Oncol; 2016 Oct; 34(28):3400-8. PubMed ID: 27325862
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant Capecitabine Following Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Clinical Trial.
    Miao J; Wang L; Tan SH; Li JG; Yi J; Ong EHW; Tan LLY; Zhang Y; Gong X; Chen Q; Xiang YQ; Chen MY; Guo Y; Lv X; Xia WX; Tang L; Deng X; Guo X; Han F; Mai HQ; Chua MLK; Zhao C
    JAMA Oncol; 2022 Oct; 8(12):1776-85. PubMed ID: 36227615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
    Ye F; Bian L; Wen J; Yu P; Li N; Xie X; Wang X
    BMC Cancer; 2022 Mar; 22(1):261. PubMed ID: 35279130
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
    Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
    JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tailoring Escalation Adjuvant Therapy for Early-Stage Triple-Negative Breast Cancer in the CBCSG010 Clinical Trial Biomarker Analysis.
    Wu W; Yang Y; Yang W; Pang D; Liu Y; Sheng Y; Li X; Yu S; Cao Y; Jiang G; Jin F; Ma B; Li J; Shao Z
    J Natl Compr Canc Netw; 2024 Oct; 22(8):528-536. PubMed ID: 39413834
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
    He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
    Trials; 2015 May; 16():238. PubMed ID: 26021722
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
    Li Q; Li Q; Zhang P; Yuan P; Wang J; Ma F; Luo Y; Fan Y; Cai R; Xu B
    Cancer Biol Ther; 2015; 16(12):1746-53. PubMed ID: 26466918
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
    Beyerlin K; Jimenez R; Zangardi M; Fell GG; Edmonds C; Johnson A; Bossuyt V; Specht M; Mulvey TM; Moy B; Ellisen LW; Isakoff SJ; Bardia A; Spring LM
    J Oncol Pharm Pract; 2021 Dec; 27(8):1883-1890. PubMed ID: 33153384
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
    Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
    Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial.
    Chen Y; Li WX; Wu JH; Chen GH; Yang CM; Lu H; Wang X; Wang SS; Huang H; Cai L; Zhao L; Peng RJ; Lin Y; Tang J; Zeng J; Zhang LH; Ke YL; Wang XM; Liu XM; Zhang AQ; Xu F; Bi XW; Huang JJ; Li JB; Pang DM; Xue C; Shi YX; He ZY; Lin HX; An X; Xia W; Cao Y; Guo Y; Hong RX; Jiang KK; Zhong YY; Zhang G; Tienchaiananda P; Oikawa M; Yuan ZY; Chen QJ
    Breast Cancer (Dove Med Press); 2024; 16():223-231. PubMed ID: 38628818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer: The Alliance A011502 Randomized Trial.
    Chen WY; Ballman KV; Partridge AH; Hahn OM; Briccetti FM; Irvin WJ; Symington B; Visvanathan K; Pohlmann PR; Openshaw TH; Weiss A; Winer EP; Carey LA; Holmes MD
    JAMA; 2024 May; 331(20):1714-1721. PubMed ID: 38683596
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
    Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
    JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
    van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S
    Eur J Cancer; 2022 May; 166():185-201. PubMed ID: 35305453
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.
    Yap YS; Kwok LL; Syn N; Chay WY; Chia JWK; Tham CK; Wong NS; Lo SK; Dent RA; Tan S; Mok ZY; Koh KX; Toh HC; Koo WH; Loh M; Ng RCH; Choo SP; Soong RCT
    JAMA Oncol; 2017 Nov; 3(11):1538-1545. PubMed ID: 28715540
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of Reduced-Dose Capecitabine Plus Cetuximab as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Clinical Trial.
    Wang L; Liu Y; Yin X; Fang W; Xiong J; Zhao B; Zhang M; Zou Y; Qiu H; Yuan X
    JAMA Netw Open; 2020 Jul; 3(7):e2011036. PubMed ID: 32687588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.